Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
OncoSil Medical Ltd ( (AU:OSL) ) has shared an announcement.
OncoSil Medical Ltd announced the issuance of 2,322 ordinary shares without disclosure under Part 6D.2 of the Corporations Act, confirming compliance with relevant legal provisions and the absence of excluded information. This move reflects the company’s ongoing efforts to strengthen its financial position and support its strategic initiatives in the medical device sector, particularly in expanding the reach and application of its OncoSil™ device for pancreatic cancer treatment.
The most recent analyst rating on (AU:OSL) stock is a Hold with a A$1.00 price target. To see the full list of analyst forecasts on OncoSil Medical Ltd stock, see the AU:OSL Stock Forecast page.
More about OncoSil Medical Ltd
OncoSil Medical Ltd is a global medical device company specializing in Interventional Oncology, aiming to enhance cancer treatment outcomes through the intratumoural placement of Phosphorous-32 Microparticles alongside chemotherapy. The company has developed the OncoSil™ device for treating unresectable locally advanced pancreatic cancer, offering a targeted approach that delivers higher radiation doses directly to tumors while sparing surrounding organs. OncoSil™ has received CE Marking approval and is recognized as a breakthrough device in Europe and the United States, with commercial availability in over 30 countries.
Average Trading Volume: 40,822
Technical Sentiment Signal: Sell
Current Market Cap: A$22.78M
See more insights into OSL stock on TipRanks’ Stock Analysis page.